August 26, 2019

Ivy Brain Tumor Center and Salarius Pharmaceuticals Launch Collaborative Partnership to Develop New Cancer Treatment for Glioblastoma

Comprehensive pre-clinical study will test first-in-class investigational therapy Seclidemstat


PHOENIX, AZ / HOUSTON, TX – August 26, 2019 – The Ivy Brain Tumor Center at the Barrow Neurological Institute and Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), today announced a collaborative partnership to test Salarius’ therapeutic candidate, Seclidemstat, for the treatment of glioblastoma. The organizations will launch what they believe is the most comprehensive pre-clinical study to date, evaluating the effect of targeting LSD1 (lysine-specific histone demethylase 1A), a key enzyme that has increased expression in tumors of brain cancer patients.



Jeremy Feffer LifeSci Advisors, Managing Director
Download PDF